You are here: Home » PTI Stories » National » News
Business Standard

NPPA fixes price of 39 drug formulation packs

Press Trust of India  |  New Delhi 

National drug price regulator NPPA has fixed the prices of 39 formulation packs including drugs used to treat diseases such as diabetes, infections, digestive disorders and pain among others.

In a statement, National Pharmaceutical Pricing Authority (NPPA) said it "has fixed/revised the prices in respect of 39 formulation packs..."

As per the notification the prices of formulations including Ciprofloxacin Hydrochloride, Cefotaxime, Paracetamol, Domperidone and Metformin+Glimepiride has been fixed.

Earlier in may, the drug price regulator NPPA had fixed prices of 30 formulation packs, including drugs used to treat various diseases such as tuberculosis, diabetes, asthma and antibiotics.

At present, the government caps prices of essential drugs based on the simple average of all medicines in a particular therapeutic segment with sales of more than 1 per cent.

Besides, the government regulates prices of all other medicines and companies are allowed to hike prices of such drugs by only up to 10 per cent in a year.

The government had notified DPCO, 2013, which covers 680 formulations, with effect from May 15, 2014, replacing the 1995 order that regulated prices of only 74 bulk drugs.

Established in 1997, NPPA has been entrusted with the task of fixation/revision of prices of pharmaceutical products (bulk drugs and formulations), enforcement of provisions of the Drugs (Prices Control) Order and monitoring of prices of controlled and decontrolled drugs in the country.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, July 15 2015. 20:57 IST
RECOMMENDED FOR YOU